Comparative Pharmacology
Head-to-head clinical analysis: MEDROXYPROGESTERONE ACETATE versus PROGESTERONE VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEDROXYPROGESTERONE ACETATE versus PROGESTERONE VAGINAL.
MEDROXYPROGESTERONE ACETATE vs Progesterone (Vaginal)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Medroxyprogesterone acetate is a progestin that binds to progesterone receptors, inhibiting gonadotropin secretion (LH, FSH) from the pituitary, thereby suppressing ovulation and altering the endometrial lining.
Progesterone binds to progesterone receptors in the reproductive tract, converting proliferative endometrium to secretory endometrium, and reduces gonadotropin secretion, inhibiting ovulation.
150 mg IM every 3 months for contraception; 400-1000 mg IM weekly for endometrial cancer; 5-10 mg PO daily for secondary amenorrhea.
For progesterone deficiency (e.g., assisted reproductive technology, luteal phase support): 90 mg intravaginally once daily. For secondary amenorrhea: 45 mg intravaginally every other day for up to 12 doses, then 90 mg if needed. For threatened abortion: 200-400 mg intravaginally once or twice daily.
None Documented
None Documented
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Deslanoside
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMedroxyprogesterone acetate + Acetyldigitoxin
Terminal elimination half-life is approximately 12-17 hours after oral administration; with depot intramuscular injection, the half-life is prolonged (up to 50-60 days due to slow release from injection site).
The terminal elimination half-life of progesterone administered vaginally is approximately 5.5 to 6 hours (range: 4.5–8.0 hours) in women with normal renal and hepatic function. This short half-life necessitates twice-daily dosing for sustained effects.
Primarily metabolized in the liver; metabolites are excreted in urine (50-70%) and feces (30-50%). Less than 5% excreted unchanged in urine.
Primarily hepatic metabolism; about 50-60% of metabolites are excreted renally as glucuronide conjugates, with approximately 30-40% eliminated via feces. Less than 1% of unchanged progesterone is excreted in urine.
Category D/X
Category A/B
Progestin
Progestin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Acetyldigitoxin."